Type of MRI contrast, tissue gadolinium, and fibrosis

被引:40
作者
Do, Catherine [1 ]
Barnes, Jeffrey L. [1 ,2 ]
Tan, Chunyan [1 ]
Wagner, Brent [2 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[2] South Texas Vet Hlth Care Syst, San Antonio, TX USA
关键词
gadolinium/adverse effects; magnetic resonance imaging/adverse effects; nephrogenic fibrosing dermopathy; skin diseases; animals; fibrosis; NEPHROGENIC SYSTEMIC FIBROSIS; KIDNEY-DISEASE; AGENTS; BIODISTRIBUTION; DERMOPATHY; SKIN; CONSEQUENCES; FIBROBLASTS; GADOTERIDOL; GADODIAMIDE;
D O I
10.1152/ajprenal.00379.2014
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
It has been presupposed that the thermodynamic stability constant (K-therm) of gadolinium-based MRI chelates relate to the risk of precipitating nephrogenic systemic fibrosis. The present study compared low-K-therm gadodiamide with high-K-therm gadoteridol in cultured fibroblasts and rats with uninephrectomies. Gadolinium content was assessed using scanning electron microscopy equipped with energy-dispersive X-ray spectroscopy in paraffin-embedded tissues. In vitro, fibroblasts demonstrated dose-dependent fibronectin generation, transforming growth factor-beta production, and expression of activated myofibroblast stress fiber protein alpha-smooth muscle actin. There were negligible differences with respect to toxicity or proliferation between the two contrast agents. In the rodent model, gadodiamide treatment led to greater skin fibrosis and dermal cellularity than gadoteridol. In the kidney, both contrast agents led to proximal tubule vacuolization and increased fibronectin accumulation. Despite large detectable gadolinium signals in the spleen, skin, muscle, and liver from the gadodiamide-treated group, contrast-induced fibrosis appeared to be limited to the skin and kidney. These findings support the hypothesis that low-Ktherm chelates have a greater propensity to elicit nephrogenic systemic fibrosis and demonstrate that certain tissues are resistant to these effects.
引用
收藏
页码:F844 / F855
页数:12
相关论文
共 40 条
[1]   Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites [J].
Abe, R ;
Donnelly, SC ;
Peng, T ;
Bucala, R ;
Metz, CN .
JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7556-7562
[2]   Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis [J].
Agarwal, Rajender ;
Brunelli, Steven M. ;
Williams, Kendal ;
Mitchell, Matthew D. ;
Feldman, Harold I. ;
Umscheid, Craig A. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (03) :856-863
[3]   Biodistribution of Gadolinium-Based Contrast Agents, Including Gadolinium Deposition [J].
Aime, Silvio ;
Caravan, Peter .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2009, 30 (06) :1259-1267
[4]  
[Anonymous], ACR MAN CONTR MED
[5]   The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses [J].
Bellini, Alberto ;
Mattoli, Sabrina .
LABORATORY INVESTIGATION, 2007, 87 (09) :858-870
[6]   Gadolinium deposition in nephrogenic fibrosing dermopathy [J].
Boyd, Alan S. ;
Zic, John A. ;
Abraham, Jerrold L. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (01) :27-30
[7]   Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear [J].
Cowper, SE ;
Bucala, R .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2003, 25 (04) :358-358
[8]   Nephrogenic fibrosing dermopathy [J].
Cowper, SE ;
Su, LD ;
Bhawan, J ;
Robin, HS ;
LeBoit, PE .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2001, 23 (05) :383-393
[9]   Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis [J].
Edward, M. ;
Quinn, J. A. ;
Mukherjee, S. ;
Jensen, M-BV ;
Jardine, A. G. ;
Mark, P. B. ;
Burden, A. D. .
JOURNAL OF PATHOLOGY, 2008, 214 (05) :584-593
[10]  
European Medicines Agency, QUEST ANSW REV GAD C